Abstract:The WHO recommends dolutegravir as part of first-line antiretroviral therapy (ART) for persons living with HIV [1]. Consequently, pregnant women living with HIV (WLHIV) are increasingly receiving dolutegravir-based ART worldwide. Although some studies have reported on birth outcomes in this population [2], there are no data on fetal biometry in pregnant WLHIV receiving dolutegravir. We assessed the association of dolutegravir-based or efavirenz-based ART with fetal biometry, using a comparison group of HIV/ART-unexposed fetuses. We enrolled pregnant WLHIV and pregnant women without HIV between 16 and 36 weeks gestation in the Tshilo Dikotla cohort in Botswana from August 2016 to May 2019. WLHIV received tenofovir and emtricitabine and either dolutegravir (dolutegravir-based ART) or efavirenz (efavirenz-based ART) during pregnancy. Pregnancies with multiple gestations or ending in fetal demise were excluded. The study was approved by the Human Research and Development Committee in Botswana and the Institutional Review Boards at Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago. Head circumference, biparietal diameter, abdominal circumference, and femoral length Z scores from a single ultrasound performed in the second trimester were calculated using INTERGROWTH-21st standards [3]. Linear regression models were fit to assess the association of in-utero HIV/ART exposure with each fetal biometric Z score. Of the 469 pregnant women enrolled, 182 received dolutegravir-based ART, 127 efavirenz-based ART, and 160 were without HIV. WLHIV on efavirenz-based ART were oldest, followed by those on dolutegravir-based ART and those without HIV (median age 32 vs. 28 vs. 24 years, respectively, P < 0.01), highest in parity (3 vs. 2 vs. 1, respectively, P < 0.01), and least likely to have completed tertiary education (7.9% vs. 14.3% vs. 33.1%, respectively, P < 0.01). Gestational age at ultrasound was higher in WLHIV than women without HIV (28 vs. 26 weeks, P < 0.01). Viral load and CD4 values were similar between WLHIV on dolutegravir-based vs. efavirenz-based ART (Table 1). Table 1 - Fetal biometry and neonatal anthropometric Z scores by in-utero HIV/antiretroviral therapy exposure status. In-utero exposure to HIV and TDF/FTC/DTG In-utero exposure to HIV and TDF/FTC/EFV HIV/ART-unexposed P value Fetuses n = 182 n = 127 n = 160 HC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 BPD 0.1 (–0.6, 0.8) –0.0 (–0.7, 0.7) 0.1 (–0.6, 0.7) 0.464 AC 0.3 (–0.4–0.7) 0.5 (–0.2–1.0) 0.1 (–0.5–0.8) 0.172 FL 1.5 (0.7–2.0) 1.5 (0.8–2.1) 1.3 (0.5–2.1) 0.396 Estimated FW 0.6 (0.2–0.9) 0.7 (0.4–1.0) 0.5 (0.0–1.0) 0.347 Neonates n = 166 n = 144 n = 131 BW –0.2 (–0.9, 0.6) –0.1 (–0.9, 0.7) –0.1 (–0.8, 0.5) 0.575 BL 1.1 (0.0, 2.1) 1.2 (0.0, 2.0) 1.3 (–0.0, 2.4) 0.458 BHC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 AC, abdominal circumference; ART, antiretroviral therapy; BHC, birth head circumference; BL, birth length; BPD, biparietal diameter; BW, birth weight; DTG, dolutegravir; FL, fetal length; FTC, emtricitabine; FW, fetal weight; HC, head circumference; TDF, tenofovir. In unadjusted analyses, overall, Z scores for all fetal biometry measurements did not differ significantly between groups (Table 1). Findings persisted after adjusting for maternal age, height, education level, parity and alcohol use in pregnancy. Birth anthropometrics were available for 94% of infants and were similar between groups. In this cohort in Botswana, there were no differences in fetal biometry between fetuses exposed to dolutegravir-based ART, those exposed to efavirenz-based ART, and those unexposed to HIV/ART. This is the first study to evaluate fetal biometric measurements in pregnant WLHIV receiving dolutegravir. Fetal ultrasound including fetal biometry is an important tool for measuring fetal well being, anomalies, and growth, allowing early detection and subsequent management of potential in-utero conditions which may place the fetus or mother at risk for poor outcomes at birth/delivery [4]. Though our study was limited by its single site study design, small sample size, and the lack of longitudinal ultrasonography, these results appear reassuring and support the continued use of dolutegravir-based regimens in pregnancy. Larger studies with serial ultrasonography are needed to validate these findings. Acknowledgements F.M.B. drafted the first version of the article. K.M.P. and J.J. conceptualized the study. S.S. performed the data analysis. F.M.B., K.M.P., S.S., J.M., G.M., L.M.Y., and J.J. reviewed the article, whereas K.M.P., L.M.Y., and J.J. gave substantive feedback on the final version. The study was funded by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) (R01DK109881). Conflicts of interest The authors have no financial conflicts of interest to disclose.

Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study

Cardiometabolic health in pregnancy and postpartum: Findings form a prospective cohort study in South Africa

Metabolic Alterations in Mothers Living with HIV and Their HIV-Exposed, Uninfected Infants

Fetal Biometry Following In-Utero Exposure to Dolutegravir-Based or Efavirenz-Based Antiretroviral Therapy

Cardio-Metabolic Health of Offspring Exposed in Utero to Human Immuno-Deficiency Virus and Anti-Retroviral Treatment: A Systematic Review

Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study

Dynamics of the infant gut microbiota in the first 18 months of life: the impact of maternal HIV infection and breastfeeding

Longitudinal changes in mitochondrial-associated measures and insulin resistance in youth with perinatally-acquired HIV in the U.S

Gut permeability is associated with lower insulin sensitivity in youth living with perinatally-acquired HIV

Assessment of the impact of HIV infection and anti-retroviral treatment on the cardiometabolic health of pregnant mothers and their offspring (ARTMOMSBABES)

Maternal immunity shapes biomarkers of germinal center development in HIV-exposed uninfected infants

Postpartum obesity and weight gain among human immunodeficiency virus‐infected and human immunodeficiency virus‐uninfected women in South Africa

Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting

African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus

Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial

Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy

Comparison of Feeding Practices and Growth of Urbanized African Infants Aged 6-12 Months Old by Maternal HIV Status in Gauteng Province, South Africa

Inflammation and cytomegalovirus viremia during pregnancy drive sex-differentiated differences in mortality and immune development in HIV-exposed infants

High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries

A-310 Neurodevelopmental disorders and hyperlipidemia in HIV-exposed uninfected children in the Bronx, New York

Inflammatory markers in pregnancy are associated with postpartum weight in South African women living with HIV on antiretroviral therapy